Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY launch, an increase of 152% year over year ® Direct-To-Consumer campaign has activated new patients, expanded base and depth of prescribers and led to a meaningful increase in prescriptions IRVINE, Calif., August 6, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced financial results for the secon ...